SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Maritza Sandoval-Rincón, Michel Sáenz-Farret, Adán Miguel-Puga, Federico Micheli, Oscar Arias-Carrión, Rational Pharmacological Approaches for Cognitive Dysfunction and Depression in Parkinson’s Disease, Frontiers in Neurology, 2015, 6,

    CrossRef

  2. 2
    Murat Emre, Paul J. Ford, Başar Bilgiç, Ergun Y. Uç, Cognitive impairment and dementia in Parkinson's disease: Practical issues and management, Movement Disorders, 2014, 29, 5
  3. 3
    Lisa Klingelhoefer, Heinz Reichmann, Dementia – The real problem for patients with Parkinson's disease, Basal Ganglia, 2014, 4, 1, 9

    CrossRef

  4. 4
    Yongxing Yan, Lizhen Liang, Tao Xie, Yonghui Shen, Yanjing Cao, Effects of Rivastigmine Combined with Reinhartdt and Sea Cucumber Capsule in Patients with Mild-to-Moderate Parkinson’s Disease Dementia: A Pilot Study, Chinese Medicine, 2014, 05, 02, 94

    CrossRef

  5. 5
    Sean Austin O. Lim, Un Jung Kang, Daniel S. McGehee, Striatal cholinergic interneuron regulation and circuit effects, Frontiers in Synaptic Neuroscience, 2014, 6,

    CrossRef

  6. 6
    Juan C. Giugni, Michael S. Okun, Treatment of advanced Parkinsonʼs disease, Current Opinion in Neurology, 2014, 27, 4, 450

    CrossRef

  7. 7
    Thien Lim, Kelvin Chou, Hubert Fernandez, Handbook of Parkinson's Disease, Fifth Edition, 2013,

    CrossRef

  8. 8
    Thien Thien Lim, Kelvin L. Chou, Hubert H. Fernandez, Handbook of Parkinson’s Disease, 2013,

    CrossRef

  9. 9
    D. Aarsland, C. Ballard, A. Rongve, M. Broadstock, P. Svenningsson, Clinical Trials of Dementia With Lewy Bodies and Parkinson’s Disease Dementia, Current Neurology and Neuroscience Reports, 2012, 12, 5, 492

    CrossRef

  10. 10
    Per Svenningsson, Eric Westman, Clive Ballard, Dag Aarsland, Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment, The Lancet Neurology, 2012, 11, 8, 697

    CrossRef

  11. 11
    Oscar Bernal-Pacheco, Natlada Limotai, Criscely L. Go, Hubert H. Fernandez, Nonmotor Manifestations in Parkinson Disease, The Neurologist, 2012, 18, 1, 1

    CrossRef

  12. 12
    Yoland Smith, Thomas Wichmann, Stewart A Factor, Mahlon R DeLong, Parkinson's Disease Therapeutics: New Developments and Challenges Since the Introduction of Levodopa, Neuropsychopharmacology, 2012, 37, 1, 213

    CrossRef

  13. 13
    Dag Aarsland, Uwe Ehrt, Irena Rektorova, Cognitive and psychiatric disturbances in Parkinson’s disease, Aging Health, 2011, 7, 1, 123

    CrossRef

  14. 14
    A. Yu. Yablonskaya, N. V. Fedorova, M. E. Belgusheva, Effects of Amantadine Sulfate on Cognitive Impairments in Patients with Parkinson’s Disease, Neuroscience and Behavioral Physiology, 2011, 41, 6, 567

    CrossRef

  15. 15
    Teus van Laar, Peter Paul De Deyn, Dag Aarsland, Paolo Barone, James E Galvin, Effects of Cholinesterase Inhibitors in Parkinson's Disease Dementia: A Review of Clinical Data, CNS Neuroscience & Therapeutics, 2011, 17, 5
  16. 16
    C. Johansson, C. Ballard, O. Hansson, S. Palmqvist, L. Minthon, D. Aarsland, E. Londos, Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment, International Journal of Geriatric Psychiatry, 2011, 26, 2
  17. 17
    Mark Stacy, Nonmotor Symptoms in Parkinson's Disease, International Journal of Neuroscience, 2011, 121, S2, 9

    CrossRef

  18. 18
    Lindy D. Wood, Joshua J. Neumiller, Stephen M. Setter, Erin K. Dobbins, Clinical review of treatment options for select nonmotor symptoms of Parkinson's disease, The American Journal of Geriatric Pharmacotherapy, 2010, 8, 4, 294

    CrossRef

  19. 19
    Karen Marder, Cognitive impairment and dementia in Parkinson's disease, Movement Disorders, 2010, 25, S1
  20. 20
    Roberto Ceravolo, Carlo Rossi, Lorenzo Kiferle, Ubaldo Bonuccelli, Nonmotor symptoms in Parkinson’s disease: the dark side of the moon, Future Neurology, 2010, 5, 6, 851

    CrossRef

  21. 21
    Dag Aarsland, Uwe Ehrt, Serge Gauthier, Rivastigmine for the treatment of Parkinson’s disease dementia, Aging Health, 2010, 6, 3, 277

    CrossRef

  22. 22
    Kapil D. Sethi, The Impact of Levodopa on Quality of Life in Patients With Parkinson Disease, The Neurologist, 2010, 16, 2, 76

    CrossRef

  23. 23
    David J. Burn, The Treatment of Cognitive Impairment Associated with Parkinson's Disease, Brain Pathology, 2010, 20, 3
  24. 24
    David John Burn, MOVEMENT DISORDERS 4, 2010,

    CrossRef

  25. 25
    Mark Stacy, Medical Treatment of Parkinson Disease, Neurologic Clinics, 2009, 27, 3, 605

    CrossRef

  26. 26
    Walter Maetzler, Stefanie Keller, Joan Michelis, Niklas Koehler, Elke Stransky, Clemens Becker, Claudia Schulte, Arthur Melms, Thomas Gasser, Daniela Berg, No differences of butyrylcholinesterase protein activity and allele frequency in Lewy body diseases, Neurobiology of Disease, 2009, 35, 2, 296

    CrossRef

  27. 27
    Heinz Reichmann, Christine Schneider, Matthias Löhle, Non-motor features of Parkinson's disease: depression and dementia, Parkinsonism & Related Disorders, 2009, 15, S87

    CrossRef

  28. 28
    Ariane Park, Mark Stacy, Non-motor symptoms in Parkinson’s disease, Journal of Neurology, 2009, 256, S3, 293

    CrossRef

  29. 29
    Elena Sinforiani, Chiara Zucchella, Chiara Pasotti, Michelangelo Bartolo, Giuseppe Nappi, Report of ten years’ activity in an Alzheimer’s disease assessment unit, Aging Clinical and Experimental Research, 2009, 21, 4-5, 365

    CrossRef

  30. 30
    Shilpa Chitnis, Jayaraman Rao, Rivastigmine in Parkinson's disease dementia, Expert Opinion on Drug Metabolism & Toxicology, 2009, 5, 8, 941

    CrossRef

  31. 31
    I. Liepelt, W. Maetzler, H.-P. Blaicher, T. Gasser, D. Berg, Behandlung der Demenz bei Parkinson-Syndromen, Der Nervenarzt, 2008, 79, 1, 36

    CrossRef

  32. 32
    Wolfgang Oertel, Werner Poewe, Erik Wolters, Peter Paul De Deyn, Murat Emre, Courtney Kirsch, Chuanchieh Hsu, Sibel Tekin, Roger Lane, Effects of Rivastigmine on Tremor and Other Motor Symptoms in Patients with Parkinson’s Disease Dementia, Drug Safety, 2008, 31, 1, 79

    CrossRef

  33. 33
    David A Gallagher, Anette Schrag, Impact of Newer Pharmacological Treatments on Quality of Life in Patients with Parkinson???s Disease, CNS Drugs, 2008, 22, 7, 563

    CrossRef

  34. 34
    Daniel D. Truong, Roongroj Bhidayasiri, Erik Wolters, Management of non-motor symptoms in advanced Parkinson disease, Journal of the Neurological Sciences, 2008, 266, 1-2, 216

    CrossRef

  35. 35
    Stefania Lalli, Alberto Albanese, Rivastigmine in Parkinson’s disease dementia, Expert Review of Neurotherapeutics, 2008, 8, 8, 1181

    CrossRef

  36. You have free access to this content36
    Mariese A. Hely, Wayne G.J. Reid, Michael A. Adena, Glenda M. Halliday, John G.L. Morris, The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years, Movement Disorders, 2008, 23, 6
  37. 37
    Miguel Coelho, Joaquim Ferreira, Mário Rosa, Cristina Sampaio, Treatment options for non-motor symptoms in late-stage Parkinson's disease, Expert Opinion on Pharmacotherapy, 2008, 9, 4, 523

    CrossRef

  38. 38
    Richard Camicioli, Serge Gauthier, Clinical Trials in Parkinson's Disease Dementia and Dementia with Lewy Bodies, The Canadian Journal of Neurological Sciences, 2007, 34, S1, S109

    CrossRef

  39. 39
    Daniel Weintraub, Matthew B Stern, Intervening in the neuropsychiatric features of Parkinson’s disease, Expert Review of Neurotherapeutics, 2007, 7, 6, 699

    CrossRef

  40. 40
    Leora L Borek, Kelvin L Chou, Joseph H Friedman, Management of the behavioral aspects of Parkinson’s disease, Expert Review of Neurotherapeutics, 2007, 7, 6, 711

    CrossRef

  41. 41
    Marco Onofrj, Astrid Thomas, Laura Bonanni, New approaches to understanding hallucinations in Parkinson’s disease: phenomenology and possible origins, Expert Review of Neurotherapeutics, 2007, 7, 12, 1731

    CrossRef

  42. 42
    Rita Moretti, Paola Torre, Cristina Vilotti, Rodolfo M. Antonello, Gilberto Pizzolato, Rivastigmine and Parkinson dementia complex, Expert Opinion on Pharmacotherapy, 2007, 8, 6, 817

    CrossRef

  43. 43
    Thomas Müller, Rivastigmine in the treatment of patients with Alzheimer's disease, Neuropsychiatric Disease and Treatment, 2007, 3, 2, 211

    CrossRef

  44. 44
    Ulrike Holzgrabe, Petra Kapková, Vildan Alptüzün, Josef Scheiber, Eva Kugelmann, Targeting acetylcholinesterase to treat neurodegeneration, Expert Opinion on Therapeutic Targets, 2007, 11, 2, 161

    CrossRef

  45. 45
    M. Emre, Treatment of dementia associated with Parkinson's disease, Parkinsonism & Related Disorders, 2007, 13, S457

    CrossRef

  46. 46
    Inga Liepelt, Walter Maetzler, Hans-Peter Blaicher, Thomas Gasser, Daniela Berg, Treatment of Dementia in Parkinsonian Syndromes with Cholinesterase Inhibitors, Dementia and Geriatric Cognitive Disorders, 2007, 23, 6, 351

    CrossRef

  47. 47
    João Carlos Machado, Paulo Caramelli, Treatment of dementia: anything new?, Current Opinion in Internal Medicine, 2007, 6, 1, 85

    CrossRef

  48. 48
    David J Burn, Cortical Lewy body disease and Parkinsonʼs disease dementia, Current Opinion in Neurology, 2006, 19, 6, 572

    CrossRef

  49. 49
    Theresa A Zesiewicz, Kelly L Sullivan, Robert A Hauser, Nonmotor symptoms of Parkinson’s disease, Expert Review of Neurotherapeutics, 2006, 6, 12, 1811

    CrossRef

  50. 50
    Mark Stacy, Joseph Jankovic, Overview of the Medical Treatment of the Non-Motor and Non-Dopaminergic Features of Parkinson's Disease,
  51. 51
    J. -P. Taylor, I. G. McKeith, The Lewy Body Dementia Spectrum (Alpha Synucleinopathies),
  52. 52
    Murat Emre, Treatment of Dementia Associated with Parkinson's Disease,